

# Distant Survival for Patients Undergoing Surgery Using Volatile versus IV Anesthesia for Hepatocellular Carcinoma with Portal Vein Tumor Thrombus:A Retrospective study.

**Xiao-Yan Meng**

second military medical university

**Xiu-Ping Zhang**

second military medical university

**Hong-Qian Wang**

Second Military Medical University

**Weifeng Yu** (✉ [ywf808@sohu.com](mailto:ywf808@sohu.com))

second military medical university <https://orcid.org/0000-0002-4349-347X>

---

## Research article

**Keywords:** Hepatocellular Carcinoma, Portal Vein Tumor Thrombus, volatile inhalational anesthesia, total IV anesthesia

**Posted Date:** February 20th, 2020

**DOI:** <https://doi.org/10.21203/rs.2.15935/v2>

**License:** © ⓘ This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

---

**Version of Record:** A version of this preprint was published on September 14th, 2020. See the published version at <https://doi.org/10.1186/s12871-020-01111-w>.

# Abstract

**Background** Whether anesthesia type is associate with the surgical outcome of Hepatocellular carcinoma (HCC) patients with portal vein tumor thrombus (PVTT) remains to be determined. This study aims to investigate the impact of volatile inhalational anesthesia (INHA) versus total IV anesthesia (TIVA) on the survival outcomes in HCC patients with PVTT.

**Methods** A cohort of in-patients whom were diagnosed of HCC with PVTT in Eastern Hepatobiliary Surgery Hospital, Shanghai, China, from January 1, 2008 to December 24, 2012 were identified. Surgical patients receiving the INHA and TIVA were screened out. The overall survival (OS), recurrence-free survival (RFS) and several postoperative adverse events were compared according to anesthesia types.

**Results** A total of 1513 patients were included in this study. After exclusions are applied, 263 patients remain in the INHA group and 208 in the TIVA group. Patients receiving INHA have a lower 5-year overall survival rate than that of patients receiving TIVA [12.6% (95% CI, 9.0 to 17.3) vs. 17.7% (95% CI, 11.3 to 20.8),  $P=0.024$ ]. Results of multivariable Cox-regression analysis also identify that INHA anesthesia is significantly associated with mortality and cancer recurrence after surgery compare to TIVA, with HR (95%CI) of 1.303 (1.065, 1.595) and 1.265 (1.040, 1.539), respectively. Subgroup analysis suggested that in more severe cancer patients, the worse outcome related to INHA might be more significant.

**Conclusion** This retrospective analysis identifies that TIVA has better survival outcomes compare to INHA in HCC patients with PVTT. Future prospective researches are urgent to verify this difference and figure out underlying causes of it.

## Background

Volatile inhalational (INHA) and IV anesthesia (TIVA) are two methods commonly used in general anesthesia maintenance. Currently, several researches reported that INHA was associated with worse postoperative outcomes compare to INHA in certain types of cancers. Dr. Wigmore et al.[1] did a retrospective analysis which firstly compared long-term survival in more than 7,000 patients undergoing elective cancer surgeries, and reported that mortality of patients accepted INHA is approximately 50% greater than those accepted TIVA. Since then, more studies reported similar results in different cancers[2]. Besides from these clinical evidences, animal researches also reported that administration of volatile inhalational agents was associated with up-regulation of tumorigenic growth factors including hypoxia-inducible factors (HIFs) and insulin-like growth factor (IGF)[3, 4], which are highly associated with progression angiogenesis and cell proliferation in tumor.

Although the underlying mechanism remains unclear, these results have drawn due attention that anesthesia technique might be an independent risk factor for postoperative outcomes of most cancers, including liver cancer. Of note, previous studies also reported that the MAC of sevoflurane is lower in patients with end-stage liver cancer[5]. Thus, we hypothesize that INHA might be associated with lower 5-year overall survival (OS) compared with TIVA in hepatocellular carcinoma (HCC) patients with portal vein

tumor thrombus (PVTT), an end-stage liver cancer with a high recurrence rate and reduced median survival time (MST) [7-10], in considering that in these end stage cancer patients, even subtle differences in medication might lead to significant effects on long-term outcome.

## Methods

### Study design

We retrospectively identified all patients who underwent aggressive surgical liver resection for selected HCC patients with PVTT at Eastern Hepatobiliary Surgery Hospital from January 1, 2008 to December 24, 2012. Exclusion criteria including: (1) no surgical treatment performed; (2) received mixed inhalational and intravenous anesthesia; (3) received additional procedures with different anesthesia or for other diseases afterwards; (4) received extra sedation in ICU or in general ward after surgery; (5) less than 18 years old; (6) had an urgent or emergency surgery and (7) incomplete follow-up data. The research was approved by the Ethics Committee of the Eastern Hepatobiliary Surgical Hospital of China. Written informed consents were obtained from participants or their surrogates during hospitalization.

Baseline data retrospectively extracted including anesthetic technique, year of surgery, age at the time of surgery, sex, American Society of anesthesiologists' (ASA) physical status classification, pre-existing diagnosis of diabetes or hypertension, HBV surface antigen (HBsAg) and HCV anti-body (HCV-ab). Data related to patients' preoperative liver function and cancer statue were also documented, including Child-Pugh score, alpha-fetoprotein (AFP), type of PVTT, tumor diameter as well as alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels.

### Outcomes

The primary outcome was 5-year OS. Secondary outcomes were (1) recurrence-free survival (RFS); (2) 30-day mortality; (3) a set of major adverse cardiac events (MACE) that included myocardial infarction (MI), cardiac arrest, or newly diagnosed malignant arrhythmia; (4) multiple organ dysfunction (MOD) primarily induced of acute hepatic failure postoperatively; (5) blood loss and blood transfusion; (6) hospital length of stay (7) postoperative ALT and AST were also recorded.

### Anesthesia techniques

Patients were divided based on INHA or TIVA they received for maintenance of anesthesia. Patients in the TIVA group received continuous infusions of propofol, and those in the INHA group received sevoflurane. Supplementary opioid for maintaining were used at the discretion of the anesthetist in all patients, including sufentanil and/or remifentanil, with the highest dose no more than 50 mg and 2 mg, respectively. No other sedative-hypnotic drugs were used during maintenance.

Type of anesthesia was according to the anesthetist's decision, mainly depending on their preference and proficiency of the anesthesia technique. Details of the surgical process as previously described[6].

## Statistical Analyses

The Kaplan–Meier method was used to calculate the overall survival and recurrence-free survival of patients from the date of surgery to the date of events. A univariable Cox regression analysis was applied, and for variables with P less than 0.1 were then included into the multivariable model to identify risk factors.

Secondary outcomes were compared using chi-square or Mann-Whitney-Wilcoxon tests as appropriate. Missing values (all less than 5%) were filled by the average value of the variable. Significant difference defined as  $P < 0.05$  in all analysis (SPSS version 22.0; IBM Inc., USA).

## Results

### Baseline characters and survival for all patients

A total of 1523 patients whom are diagnosed of HCC with PVTT are delivered in the study period. After exclusions applied, 471 patients are included in the analysis, with 263 patients in the INHA group and 208 in the TIVA (**Figure 1**). The mean age is 48.6 years old ; The majority of patients are male (90.6%), had a grade of ASA II (88.3%) and Child-Pugh A (88.4%); 410 (87.0%) of patients have large hepatocellular carcinoma (>10cm).; 408 (86.6%) are identified with HBsAg+, including 4 with both HBsAg+ and HCV-ab+. Only 4 patients are identified with HCV-ab+ alone, which is not enough for effective analysis. Five-year survival rate for all patients is 14.8% (95% CI, 11.3 to 17.6), with median survival time of 9.0 month (95% CI, 7.9 to 10.0). The patient characteristics in two groups are described in **Table 1**.

### Five-year OS and RFS

Results of Kaplan–Meier survival analysis show that, compare with TIVA, INHA is associated with a worse 5-year OS rate [17.7% (95% CI, 11.3 to 20.8 VS. 12.6% (95% CI, 9.0 to 17.3));  $P=0.024$ , **Figure 2, A**], as well as a worse 5-year RFS rate [15.4% (95% CI, 12.6 to 18.1) VS. 11.7% (95% CI, 9.7 to 13.8);  $P=0.032$ , **Figure 2, B**]. On univariable analysis, 6 potential risk factors have  $P < 0.1$  are included in multivariable model (Supplementary table 1). Results of multivariable analysis also suggest that INHA is an independent risk factor for mortality [HR (95%CI), 1.303 (1.065, 1.595)] and cancer recurrence [HR (95% CI), 1.265 (1.040, 1.539); **Table 2**] in 5 years after surgery.

### Other Secondary outcomes

Other outcomes including 30-day mortality rate, postoperative MACE and MOF rate, as well as blood loss, blood transfusion and length of stay in hospital are similar in both groups (**Table 3**). Postoperative serum biomarker of ALT and AST are compared (with incomplete data), the results suggest a better liver function of TIVA after surgery (Supplementary Figure 1).

### Subgroup analysis

In multivariable model, four more variables are screened out as independent risk factors for 5-year OS and RFS: Child-Pugh, AFP level, diameter of hepatocellular carcinoma and PVTT type. We then did a subgroup Kaplan–Meier survival analysis to estimate the association of anesthesia type on postoperative OS and RFS in different sub-variable groups, there were Child-Pugh A; Child-Pugh B&C; tumor diameter<10cm; tumor diameter≥10cm; AFP<400ug/L; AFP≥400ug/L; PVTT typeⅠ; PVTT typeⅡ; PVTT typeⅢ. The results suggest that INHA was associated with significant lower OS and RFS rate compare with TIVA in several sub-variable groups indicating more severe liver cancer statuses, including tumor diameter≥10cm (**Figure 4B, 4D**); AFP≥400ug/L (**Figure 5B, 5D**); PVTT typeⅠand PVTT typeⅡ(**Figure 6C, 6E, 6F**).

## Discussion

This retrospective analysis of 1513 HCC patients with PVTT evaluates long-term OS, RFS and several short-term postoperative adverse events in surgical patients receiving INHA using sevoflurane and TIVA using propofol. We identify that patients receiving INHA had a lower 5-year OS and RFS rate than that of patients receiving TIVA. On multivariable Cox regression analysis, INHA is an independent risk factor for mortality and cancer recurrence in 5-year after surgery. In subgroup analysis, patients accepted INHA, compare with those who accepted TIVA, have worse survival rates when there are in severe liver cancer statuses. No significant differences in postoperative adverse events and 30-day mortality are found between the two groups in this study.

### Clinical Evidence of anesthesia type on surgical outcomes

Recently, several clinical studies with large sample sizes have been investigated for anesthesia type on postoperative outcomes in elective cancer patients. In a retrospective analysis based on 2,838 patients with breast, rectal, and colon cancer, Enlund et al.[7] firstly reported that overall survival for patients receiving propofol anesthesia is 4.7% higher at 1-yr and 5.6% at 5-yr than those receiving sevoflurane. But after balance for confounders, this differences are not significant. In another study, Wigmore et al.[1] analyzed 7,030 patients who underwent elective cancer surgery over a 3-yr period, They reported a worse outcome in patients receiving volatile anesthesia, with a HR of 1.46 (95% CI, 1.29 to 1.66) for death, compare with TIVA. In addition, Yan et al[8]. designed a randomized controlled trail in 80 breast cancer patients and identified that total intravenous anesthesia can inhibit the release of VEGF-C induced by breast surgery, yet with no significant benefice in the short-term recurrence rate of breast cancer. Importantly, a recent meta-analysis with 9 retrospective studies and 1 RCT concluded that, the use of TIVA was associated with improved RFS in all cancer types and improved OS in several certain types of cancers[2]. These studies have achieved consistent results that TIVA anesthesia has a better long-term prognosis for patients undergoing tumor resection compared with INHA, nevertheless, the population they enrolled varies a lot. As such, meaningful conclusions on whether TIVA is superior to INHA for all cancer patients or just for certain types of cancer are difficult to define. To this end, the current study sort to compare long-term survival rate in TIVA and INHA in HCC patients with PVTT.

## Laboratory evidence of anesthetics on tumors metastasis and recurrence

Over the years, numerous animal and laboratory studies have been investigated for the mechanism of anesthetic agents on primary tumors metastasis and recurrence. Cellular immune system and tumor proliferation-associated factors are considered to play a key role in it. Of note, propofol has been demonstrated to have preservation effective on T lymphocyte activity and Th1 cytokine secretion, or even inhibits tumor growth in animal model[9-11]. Specifically, T lymphocytes and NK cells are two major cytotoxic effector cells that participate in cell-mediated immune responses. Meanwhile, researches also proved that sevoflurane could inhibit primary leukocyte integrin lymphocyte function and induced lymphocyte apoptosis through downregulation of LFA-1, thus promoting tumor recurrence and metastasis[12]. Moreover, studies both in vivo[13] and in patients undergoing breast cancer surgery[14] have reported an inhibitory effect of anesthetic agents on natural killer cell function. According to their description, this effect is probably related to the dysfunction in CD16 cell and CD107a NK receptor after exposure to sevoflurane[15]. More recently, Bellanti et al.[16] demonstrated that propofol, not sevoflurane, prevents mitochondrial dysfunction and oxidative stress by limiting hypoxia-inducible factor 1 alpha (HIF-1 $\alpha$ ) activation in hepatic ischemia/reperfusion injury. according to their description, this change could be beneficial for liver function, as HIF-1 $\alpha$  governs the transcription of genes controlling proliferation and metastasis of tumor cells[17, 18]. Additionally, previous researches already demonstrate that isoflurane administration could result in an up-regulation of HIF-1 $\alpha$  in tumor[19]. However, there have no solid evidence to prove those theory in human body, while the molecular mechanisms of the different outcomes of the two anesthetic methods remains to be determined yet.

## HCC with PVTT

HCC ranges as the fifth most common malignancy tumor[20]. Indeed, even worse prognosis is reported in HCC patients with PVTT, with a reported rate of 20% and a reduced median survival time (MST) of around 2-4 months compared to patients without PVTT[21-24]. According to the Asia-Pacific guideline, surgery is recommended as one of the beneficial multidisciplinary treatments for PVTT. Moreover, aggressive surgical resection is associated with a longer survival outcome, and even provide chances for complete cure with type I and II PVTT[25, 26]. Meanwhile, recent studies reported that under advanced perioperative management and skilled surgical operation, the in-hospital mortality of HCC patients with PVTT arrives an acceptable rate ranging from 3.7% to 10%[27, 28]. However, the knowledge about risk factors for postoperative mortality, cancer recurrence and other side events of HCC patients with PVTT still remains insufficient. Our result provides with extra evidence that anesthesia type might be a risk factor for surgical outcomes of HCC patients with PVTT.

## Limitations

Several methodological discrepancies and limitations of this study should be discussed. First, there might be inclusion bias exist in our cohort, as more than a thousand patients were excluded with only 471 enrolled. Meanwhile, the majority of included patients are male, with ASA score of II, Child-Pugh score of A, and large tumor size over 10cm. Second, certain clinical data of treatment are not collected, including

perioperative chemoradiotherapy, detailed surgical techniques, and usage of opioids during surgery. Opioids have been reported to have an effect on tumor cell proliferation and angiogenesis, as well as on tumor recurrence and metastasis. However, it's hard to accurately record and compare total amounts of opioid used in both groups during surgery as they are administered both continuously or intermittently. In this study all patients accepted at least one of remifentanil or sufentanil treatment in standard dose. Besides, since this is a retrospective analysis based clinical records and follow up data, the reason for the choice of anesthesia type at that time point, as well as potential factors affecting this choice, are not recorded or balanced. Thus, prospective researches with rigorous study design and large sample size on this field are in urgent need.

In conclusion, this retrospective analysis of long-term outcomes identifies that INHA is associated with worse survival rate compare with TIVA, and the choice of anesthesia type might be an independent risk factor for survival of HCC patients with PVTT. Future prospective researches are urgent to verify this difference and figure out underlying causes of it.

## List Of Abbreviations

HCC: Hepatocellular carcinoma; PVTT: portal vein tumor thrombus; INHA: volatile inhalational anesthesia; TIVA: total IV anesthesia; OS: overall survival; MST: median survival time; HIFs: hypoxia-inducible factors; IGF: and insulin-like growth factor; MACE: major adverse cardiac events; MOD: multiple organ dysfunction; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; NLR: neutrophil-lymphocyte ratio; ASA: American Society of anesthesiologists' Assessment; AFP: alpha-fetoprotein.

## Declarations

### **Ethics approval and consent to participate.**

This trial had approval from the ethics committee of Eastern Hepatobiliary Surgical Hospital (EHBHHKY2012-02-028). All subjects participating in the current trial provided signed informed consent.

### **Consent for publication.**

Not applicable.

### **Availability of data and materials.**

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

### **Competing interests.**

The authors declare that they have no competing interests.

## Funding.

This study was supported by grants from the National Natural Science Foundation of China (No. 81571048); Pudong New Area Health and Family Planning Commission Joint Research Project (PW2015D-3).

## Authors' contributions

XYM helped conduct the study, analyze the data, and write the manuscript; XPZ and HQW conducted the study and analyze the data; conducted the study and analyzed the data; WFY helped design the study and revise the manuscript.

## Acknowledgements

The authors thank Han Wang, M.D. for his contributions to data analysis.

## References

1. Wigmore TJ, Mohammed K, Jhanji S: **Long-term Survival for Patients Undergoing Volatile versus IV Anesthesia for Cancer Surgery: A Retrospective Analysis.** *Anesthesiology* 2015, **60**(6):240.
2. A Y, MA L-O, J D, J H, B R: **Anesthetic technique and cancer outcomes: a meta-analysis of total intravenous versus volatile anesthesia.** *Canadian journal of anaesthesia = Journal canadien d'anesthesie* 2019, **66**(5):546-561.
3. Huang H, Benzonana LL, Zhao H, Watts HR, Perry NJ, Bevan C, Brown R, Ma D: **Prostate cancer cell malignancy via modulation of HIF-1 $\alpha$  pathway with isoflurane and propofol alone and in combination.** *British Journal of Cancer* 2014, **111**(7):1338-1349.
4. Luo X, Zhao H, Hennah L, Ning J, Liu J, Tu H, Ma D: **Impact of isoflurane on malignant capability of ovarian cancer in vitro  $\ddagger$ .** *British Journal of Anaesthesia* 2015, **114**(5):831-839.
5. Fujita Y, Kimura K, Hamada H, Takaori M: **Comparative effects of halothane, isoflurane, and sevoflurane on the liver with hepatic artery ligation in the beagle.** *Anesthesiology* 1991, **75**(2):313-318.
6. Shi J, Lai ECH, Li N, Guo WX, Xue J, Wan YL, Wu MC, Cheng SQ: **Surgical Treatment of Hepatocellular Carcinoma with Portal Vein Tumor Thrombus.** *Annals of Surgical Oncology* 2010, **17**(8):2073-2080.
7. Enlund M, Berglund A, Andreasson K, Cicek C, Enlund A, Bergkvist L: **The choice of anaesthetic—sevoflurane or propofol—and outcome from cancer surgery: A retrospective analysis.** *Upsala Journal of Medical Sciences* 2014, **119**(3):251-261.
8. T Y, GH Z, BN W, L S, H Z: **Effects of propofol/remifentanil-based total intravenous anesthesia versus sevoflurane-based inhalational anesthesia on the release of VEGF-C and TGF- $\beta$  and prognosis after breast cancer surgery: a prospective, randomized and controlled study.** *BMC anesthesiology* 2018, **18**(1):131.

9. He FY, Feng WZ, Zhong J, Xu W, Shao HY, Zhang YR: **Effects of propofol and dexmedetomidine anesthesia on Th1/Th2 of rat spinal cord injury.** 2017, **21**(6):1355-1361.
10. Kushida A, Inada T, Shingu K: **Enhancement of antitumor immunity after propofol treatment in mice.** *Immunopharmacol Immunotoxicol* 2007, **29**(3-4):477-486.
11. Liu J, Dong W, Wang T, Liu L, Zhan L, Shi Y, Han J: **Effects of etomidate and propofol on immune function in patients with lung adenocarcinoma.** *American Journal of Translational Research* 2016, **8**(12):5748.
12. Yuki K, Astrof NS, Bracken C, Soriano SG, Shimaoka M: **Sevoflurane Binds and Allosterically Blocks Integrin Lymphocyte Function-associated Antigen-1.** *Anesthesiology* 2010, **113**(113):600-609.
13. Melamed R, Bar-Yosef S, Shakhar G, Shakhar K, Ben-Eliyahu S: **Suppression of natural killer cell activity and promotion of tumor metastasis by ketamine, thiopental, and halothane, but not by propofol: mediating mechanisms and prophylactic measures.** *Anesthesia & Analgesia* 2003, **97**(5):1331-1339.
14. Buckley A, Quaid MS, Johnson P, Buggy D: **Serum from women undergoing breast cancer surgery, randomized to propofol-paravertebral anaesthetic technique, maintain natural killer cell anti-tumour activity compared with sevoflurane-opioid technique.** *European Journal of Anaesthesiology* 2014, **31**:2.
15. Buckley A, Mcquaid S, Johnson P, Buggy DJ, Hemmings HC: **Effect of anaesthetic technique on the natural killer cell anti-tumour activity of serum from women undergoing breast cancer surgery: a pilot study.** *British Journal of Anaesthesia* 2014, **113**(suppl 1):i56–i62.
16. Bellanti F, Mirabella L, Mitarotonda D, Blonda M, Tamborra R, Cinnella G, Fersini A, Ambrosi A, Dambrosio M, Vendemiale G: **Propofol but not sevoflurane prevents mitochondrial dysfunction and oxidative stress by limiting HIF-1 $\alpha$  activation in hepatic ischemia/reperfusion injury.** *Free Radical Biology & Medicine* 2016, **96**:323-333.
17. Semenza GL: **Hypoxia-inducible factors: mediators of cancer progression and targets for cancer therapy.** *Trends in Pharmacological Sciences* 2012, **33**(4):207-214.
18. Semenza GL: **HIF-1 mediates metabolic responses to intratumoral hypoxia and oncogenic mutations.** *Journal of Clinical Investigation* 2013, **123**(9):3664-3671.
19. Li QF, Wang XR, Yang YW, Su DS: **Up-regulation of hypoxia inducible factor 1alpha by isoflurane in Hep3B cells.** *Anesthesiology* 2006, **105**(6):1211-1219.
20. Bruix J, Reig M, Sherman M: **Evidence-Based Diagnosis, Staging, and Treatment of Patients With Hepatocellular Carcinoma.** *Gastroenterology* 2016, **150**(4):835.
21. Bruix J, Sherman M: **Management of hepatocellular carcinoma: an update. american association for the study of liver diseases (AASLD) practice guideline.** *Hepatology* 2011, **53**:1020-1035.
22. Schölten-Hekele M, Müller C, Kutilek M, Oesterreicher C, Ferenci P, Gangl A: **Hepatocellular carcinoma in Central Europe: prognostic features and survival.** *Gut* 2001, **48**(1):103-109.
23. Balogh J, Victor D, Asham EH, Burroughs SG, Boktour M, Saharia A, Xian L, Ghobrial RM, Monsour HP: **Hepatocellular carcinoma: a review.** *Journal of Hepatocellular Carcinoma* 2016, **3**:41-53.

24. Yeung YP, Lo CM, Liu CL, Wong BC, Fan ST, Wong J: **Natural History of Untreated Nonsurgical Hepatocellular Carcinoma.** *American Journal of Gastroenterology* 2005, **100**(9):1995-2004.
25. Kokudo T, Hasegawa K, Matsuyama Y, Takayama T, Izumi N, Kadoya M, Kudo M, Ku Y, Sakamoto M, Nakashima O: **Survival benefit of liver resection for hepatocellular carcinoma associated with portal vein invasion.** *Journal of Hepatology* 2016, **65**(5):938-943.
26. Shi J, Lai EC, Li N, Guo WX, Xue J, Lau WY, Wu MC, Cheng SQ: **Surgical treatment of hepatocellular carcinoma with portal vein tumor thrombus.** *Annals of Surgical Oncology* 2010, **17**(8):2073-2080.
27. Chen JS, Wang Q, Chen XL, Huang XH, Liang LJ, Lei J, Huang JQ, Li DM, Cheng ZX: **Clinicopathologic Characteristics and Surgical Outcomes of Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis.** *Journal of Surgical Research* 2012, **175**(2):243-250.
28. Chok KS, Cheung TT, Chan SC, Poon RT, Fan ST, Lo CM: **Surgical outcomes in hepatocellular carcinoma patients with portal vein tumor thrombosis.** *World Journal of Surgery* 2014, **38**(2):490-496.

## Tables

Table 1. Patient Baseline Characters.

Variables	TIVA (N=208)	INHA (N=263)	P value
	N (%)	N (%)	
Sex (male)	188 (90.4)	239 (90.9)	0.856
HBsAg-+ <sup>\$</sup>	182 (87.5)	226 (85.9)	0.619
ASA			
II	186 (89.4)	229 (87.1)	0.191
III	22 (10.6)	30 (11.4)	
IV	0 (0)	4 (1.5)	
Child-Pugh			
A	184 (88.5)	233 (88.6)	0.662
B	22 (10.6)	25 (9.5)	
C	2 (0.4)	5 (1.1)	
AFP (ug/L)			
<25	30 (14.4)	54 (20.5)	0.109
25-399	39 (18.8)	45 (17.1)	
400-999	12 (5.8)	25 (9.5)	
≥ 1000	127 (61.1)	139 (52.9)	
Tumor Diameter (cm)			
<5	1 (0.4)	2 (0.8)	0.546
5-9.9	22 (10.6)	36 (13.7)	
≥10	185 (88.9)	225 (85.6)	
PVTT			
1	30 (14.4)	40 (15.3)	0.716
2	131 (63.0)	163 (62.0)	
3	47 (22.1)	60 (22.8)	
Year of surgery			
2008	70 (33.7)	79 (30.0)	0.882
2009	33 (15.9)	42 (16.0)	
2010	31 (14.9)	46 (17.5)	
2011	31 (14.9)	37 (14.1)	
2012	43 (20.7)	59 (22.4)	
Age (yr)	Mean (SD)	Mean (SD)	
	48.0 (10.94)	49.0 (9.73)	0.078
	Median (IQR)	Median (IQR)	
WBC (10 <sup>9</sup> /L)	5.5 (4.2, 7.3)	5.4 (4.3, 7.1)	0.06
ALT (U/L)	47.8 (31.0, 66.0)	45.0 (29.1, 67.3)	0.903
AST (U/L)	49.0 (37.0, 69.0)	52.0 (35.0, 71.0)	0.820

ASA = American Society of Anesthesiologists; PVTT=Portal vein tumor thrombus; INHA=Volatile inhalational anesthesia; TIVA=Total IV anesthesia; WBC=White blood cells; NLR=Neutrophil-lymphocytes ratio. \$ Including 4 patients with HBsAg-+ and anti-HCV-+.

Table 2. Cox Proportional Hazard Regression Analyses: Multivariable Model for Overall Survival and Recurrence-Free Survival.

Variables	Overall Survival		Recurrence-Free Survival		
	HR (95% CI)	<i>P</i> Value	HR (95% CI)	<i>P</i> Value	
Anesthesia type (INHA/TIVA)	1.303 (1.065, 1.595)	0.010	1.265 (1.040, 1.539)	0.019	
Child-Pugh	1.897 (1.491, 2.414)	0.000	1.653 (1.297, 2.105)	0.000	
AFP (ug/L)	1.099 (1.010, 1.194)	0.027	1.071 (0.989, 1.160)	0.093	
Tumor Diameter (cm)	1.606 (1.183, 2.181)	0.002	1.492 (1.123, 1.983)	0.006	
PVTT	1.160 (0.989, 1.360)	0.068	-	-	

\* Overall categories comparison.


ASA = American Society of Anesthesiologists; PVTT=Portal vein tumor thrombus; INHA=Volatile inhalational; TIVA=Total IV anesthesia, NLR=Neutrophil-lymphocytes ratio.

Table 3. Adverse Outcomes

	TIVA	INHA	
	N (%)	N (%)	<i>P</i> Value
<b>Dichotomous Outcomes</b>			
30-day Mortality	4 (2.1)	11 (4.7)	0.106
MACE	4 (2.1)	11 (4.7)	0.106
MOD	6 (3.3)	9 (3.9)	0.797
Blood Transfusion	80 (43.5)	78 (33.5)	0.189
	Median (IQR)	Median (IQR)	
<b>Continuous Outcomes</b>			
Blood Loss	400 (245,800)	400 (300,800)	0.301
Length of Stay (days)	15 (13,20)	16 (13,20)	0.920


IQR = interquartile range; MACE = major adverse cardiac events; MOF = multiple organ failure; RR = risk ratio..

## Figures




**Figure 1**

Flow diagram detailing the selection of patients included in the retrospective analysis. INHA = volatile inhalational; TIVA = total IV anesthesia.



**Figure 2**


Kaplan–Meier survival curves from the date of surgery by anesthesia type for (A) overall survival in patients before matching (P=0.007), (B) overall survival in patients after matching (P=0.044), (C) recurrence-free survival in patients before matching (P=0.020), (D) recurrence-free survival in patients after matching (P=0.081). INHA = volatile inhalational; TIVA = total IV anesthesia.




**Figure 3**

Subgroup Kaplan–Meier survival analysis for anesthesia type on (A) OS in Child-Pugh A; (B) OS in Child-Pugh B&C; (C) RFS in Child-Pugh A; (D) RFS in Child-Pugh B&C.


**A. OS for Tumor Diameter <10cm**




**B. OS for Tumor Diameter ≥ 10cm**



**C. RFS for Tumor Diameter <10cm**




**D. RFS for Tumor Diameter ≥ 10cm**




**Figure 4**

Subgroup Kaplan–Meier survival analysis for anesthesia type on (A) OS in tumor diameter <10cm; (B) OS in tumor diameter ≥10cm; (C) RFS in tumor diameter <10cm; (D) RFS in tumor diameter ≥10cm.


**A. OS for AFP<400ug/L**




**B. OS for AFP≥400ug/L**



**C. RFS for AFP<400ug/L**




**D. RFS for AFP≥400ug/L**



**Figure 5**

Subgroup Kaplan–Meier survival analysis for anesthesia type on (A) OS in AFP<400ug/L; (B) OS in AFP≥400ug/L; (C) RFS in AFP<400ug/L; (D) RFS in AFP≥400ug/L.



**Figure 6**

Subgroup Kaplan–Meier survival analysis for anesthesia type on (A) OS in PVTT type I; (B) OS in PVTT type II; (C) OS in PVTT type III; (D) RFS in PVTT type I; (E) RFS in PVTT type II; (F) RFS in PVTT type III.

## Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [Supplementaryfigure2.tif](#)
- [supplementaltable1.docx](#)